HUNG-HSUAN YENCHIUNG-NIEN CHENCHI-CHUAN YEHI-RUE LAI2021-11-232021-11-232021-04-171477-7819https://scholars.lib.ntu.edu.tw/handle/123456789/587684Background: Adjuvant tegafur-gimeracil-oteracil (S-1) is commonly used for gastric cancer in Asia, and tegafur-uracil (UFT) is another oral fluoropyrimidine when S-1 is unavailable. The real-world data of adjuvant UFT has less been investigated. Methods: Patients with pathological stage II-IIIB (except T1) gastric cancer receiving adjuvant UFT or S-1 monotherapy after D2 gastrectomy were included. Usage of UFT or S-1 was based on reimbursement policy of the Taiwanese healthcare system. The characteristics, chemotherapy completion rates, and 5-year recurrence-free survival (RFS) and overall survival (OS), were compared between these two groups. Results: From 2005 to 2016, 86 eligible patients were included. Most tumor characteristics were similar between the UFT group (n = 37; age 59.1 ± 13.9 years) and S-1 group (n = 49; age 56.3 ± 10.7 years), except there were significantly more Borrmann type III/IV (86.5% versus 67.3%; p = 0.047) and T4 (56.8% versus 10.2%; p < 0.001) lesions in the UFT group than in the S-1 group. The chemotherapy complete rates were similar in the two groups. The 5-year RFS was 56.1% in the UFT group and 59.6% in the S-1 group (p = 0.71), and the 5-year OS was 78.3% in the UFT group and 73.1% in the S-1 group (p = 0.48). The hazard ratio of adjuvant chemotherapy (S-1 versus UFT) on RFS was 1.25 (95% confidence interval = 0.53-2.94) when Borrmann type and T and N stages were adjusted. Conclusions: This small cohort study showed adjuvant UFT, and S-1 monotherapy had a comparable long-term outcome for pathological stage II-IIIB gastric cancer following D2 gastrectomy.enAdjuvant chemotherapyGastric cancerS-1TegafurUFT[SDGs]SDG3gimeracil plus oteracil potassium plus tegafur; UFT; antineoplastic agent; antineoplastic antimetabolite; oteracil; S 1 (combination); tegafur; uracil; adult; Article; cancer adjuvant therapy; cancer chemotherapy; cancer staging; cohort analysis; comparative study; female; gastrectomy; health care system; health insurance; human; major clinical study; male; middle aged; monotherapy; overall survival; recurrence free survival; retrospective study; stomach cancer; Taiwan; treatment outcome; adjuvant chemotherapy; aged; disease free survival; drug combination; pathology; prognosis; stomach tumor; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Prognosis; Stomach Neoplasms; Tegafur; Treatment Outcome; Uraciljournal article10.1186/s12957-021-02233-2338654162-s2.0-85104509609https://scholars.lib.ntu.edu.tw/handle/123456789/561643